2017 Annual Meeting

Apr 5, 2017 ‐ Apr 8, 2017

Standard: $250.00


SESSION 3: Moving DCD Forward: Thinking Inside the Box

Apr 5, 2017 2:30pm ‐ Apr 5, 2017 4:00pm

Identification: 003

(15) 12 Hour Hypothermic Oxygenated Machine Perfusion Preserves the Quality of Donor Hearts: A Biomarker Analysis
Sebastian Michel, MD

(16) Excellent Early Outcomes Following Heart Transplantation from Circulatory Dead Donors
Simon Messer, MD

(17) Rapid Retrieval and Ex Situ Portable Machine Perfusion Allows Successful Cardiac Transplantation with Donor Hearts from Controlled Donation After Circulatory Death
Kumud Dhital, BM.BCh, FRCS-CTh, FRACS, PhD

(18) Donor Circulatory Death Heart Transplantation with Adverse Donor and Recipient Risk Profile
Diana García Sáez, MD

(19) Does the Assessment of DCD Donor Hearts on the Organ Care System Using Lactate Need Redefining?
Aravinda Page, MBBChir, MRSC

(20) Midterm Follow up of Heart Transplantation with Routine Ex-Vivo Normothermic Preservation with Adverse Donor - Recipient Risk Profile
Diana García Sáez, MD


SESSION 4: Donor Lung Allocation Strategies

Apr 5, 2017 2:30pm ‐ Apr 5, 2017 4:00pm

Identification: 004

(21) What Effect Does Rate of Change in LAS Have on Lung Transplant Outcomes?
Alexander Aretakis, BA

(22) Lung Allocation Score Implementation Narrowed Racial/Ethnic Disparities in Adult Lung Transplantation Outcomes
Brian Lim, BA

(23) Objective Donor Scoring System for Lung Transplantation
William Whited, MD

(24) Is There a Rationale for an “Old-for-Old” Program in Lung Transplantation? A Comparative Study Using the International Society of Heart and Lung Transplantation Database
Alexander Bernhardt, MD

(25) Are Donors with Pulmonary Arterial Embolism the Better Donors for Lung Transplantation?
Wiebke Sommer, MD

(26) Use of Drug Intoxicated Donors for Lung Transplant: Impact on Survival Outcomes
William Whited, MD


SESSION 5: Registries and Risk Scores in Pulmonary Hypertension: Updates, Lessons Learned, and Practice Changes

Apr 5, 2017 2:30pm ‐ Apr 5, 2017 4:00pm

Identification: 005

(27) Updated Risk Score Calculator for Pulmonary Arterial Hypertension Patients
Raymond Benza, MD

(28) Preliminary Data from the United States CTEPH Registry
Kim Kerr, MD

(29) REVEAL Risk Score in Patients with Chronic Thromboembolic Pulmonary Hypertension Receiving Riociguat
Raymond Benza, MD

(30) OPUS Registry: Safety and Tolerability of Macitentan in a Real-World Setting
Nick Kim, MD

(31) Orthotopic Heart Lung Transplantation Improving Outcomes Over Time
Edit Nagy, MD, PhD

(32) Orthotopic Heart-Lung Transplantation: Outcomes and Predictors of Outcomes in Recipients with Eisenmenger Syndrome, Other Congenital Etiologies, and Idiopathic Pulmonary Arterial Hypertension
Edit Nagy, MD, PhD

  • Raymond L. Benza, MD, FACC, FAHA, FACP, Professor and Director, Division of Cardiovascular Diseases; Bob and Corrine Frick Endowed Chair of Heart Failure, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA
  • Kim M. Kerr, MD, La Jolla, CA, USA, UCSD Medical Center
  • Nick Kim, MD, University of California, San Diego
  • Edit Nagy, MD, PhD, Department of Cardiology, Karolinska University Hospital, Department of Medicine, Karolinska Institutet

SESSION 6: Pediatric Heart Failure: Diagnosis, Management, and Confronting Risk

Apr 5, 2017 2:30pm ‐ Apr 5, 2017 4:00pm

Identification: 006

(33) Distinct Disease Mechanisms Govern the Progression of Pediatric and Adult Dilated Cardiomyopathy
Meghna Patel, MD

(34) Diagnostic Errors at First Presentation of Heart Failure in Children
Kriti Puri, MD

(35) Hemodynamics of the Pediatric Failing Fontan
John Dykes, MD

(36) Assist Device Therapy for Myocarditis - Analysis from the German Multi-Centre Prospective Myocarditis Registry in Pediatric Patients: “Mykke”
Stephan Schubert, MD

(37) Renal Dysfunction as a Relative Contraindication to Pediatric Heart Transplantation
Ivan Wilmot, MD

(38) The Impact of Tracheostomy on Pediatric Heart Transplant Outcomes: A Multi-Institutional Analysis
Joseph Spinner, MD


SESSION 7: Cutting Edge Updates in Infectious Diseases

Apr 5, 2017 2:30pm ‐ Apr 5, 2017 4:00pm

Identification: 007

(39) Clinical Risk Factors for Invasive Aspergillosis in Lung Transplant Recipients: Results of an International Cohort Study
Claire Aguilar, Fellow

(40) Aspergillus Galactomannan Detection in Exhaled Breath Condensate for the Diagnosis of Invasive Aspergillosis in Lung Transplant Recipients
Alyajahan Bhimji, PhD

(41) Impact of Cytomegalovirus and Its Prevention Strategies on Survival in Thoracic Transplant Recipients
Jutta Preiksaitis, MD

(42) Invasive Mycobacterium abscessus Infection in Heart Transplant Recipients
Eileen Maziarz, MD

(43) Clinical and Microbiologic Characteristics of Infections in Left Ventricular Assist Device Recipients
Mary Bradbury, PharmD, BCPS

(44) Potential Posaconazole Sequestration During Extracorporeal Membrane Oxygentation: Results from an Ex-Vivo Experiment
Haifa Lyster, MSc

Tags: ID ALL

SESSION 8: Bugs and Devices: A Bad Combination

Apr 5, 2017 4:30pm ‐ Apr 5, 2017 6:00pm

Identification: 008

(45) Epidemiology of Bloodstream Infections in MCSD Recipients in the IMACS Registry
Saima Aslam, MD, MS

(46) The Epidemiology of Infection in MCS from the IMACS Database: January 2013 to December 2015
Margaret Hannan, MD

(47) Epidemiology of Fungal Infections (FI) in Mechanical Circulatory Support Device (MCSD) Recipients: Analysis of IMACS Registry 2013-2015
Orla Morrissey, MD, PhD

(48) Risk Factors and Mortality for Sepsis in Left Ventricular Assist Device Recipients
Parijat Joy, MD, MPH

(49) Supporting Imaging Modalities for Improving Diagnosis of Infection in Patients on CF-LVAD:A Single-Center Experience Including 61 Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomographies
Angello Dell'Aquila, MD

(50) Hepatitis C Virus Infection Does Not Impact Survival Following Continuous-Flow Left Ventricular Assist Device Implantation
Akshay Pendyal, MD


SESSION 9: MCS Surgery: Does Nuance Make a Master?

Apr 5, 2017 4:30pm ‐ Apr 5, 2017 6:00pm

Identification: 009

(51) A Novel Technique of Temporary Right Ventricular Assist Device (RVAD) Placement During Durable Left Ventricular Assist Device (LVAD) Implant to Allow Early Ambulation and Bedside Percutaneous Removal
Giorgio Zanotti, MD

(52) Pre-Implant Left Ventricular Apex Position Predicts Risk of HeartMate II Pump Thrombosis
Leora Yarboro, MD

(53) Surgical Strategy to Support Right Ventricle with HVAD RVAD: Right Atrial vs Right Ventricular Diaphragmatic Surface Cannulation
Katsuhide Maeda, MD

(54) Should Prophylactic Tricuspid Valve Surgery Be Considered in Patients with Atrial Fibrillation Undergoing LVAD Implantation?
Vakhtang Tchantchaleishvili, MD

(55) Outcomes of Multiple Concomitant Valve Procedures in Patients Receiving Continuous-Flow Left Ventricular Assist Device
Jiho Han, BS

(56) First-in-Human (FIH) Experience with the Intravascular Ventricular Assist System iVAS a Novel Approach to Mechanical Circulatory Support
Valluvan Jeevanandam, MD


SESSION 10: Movement on the Heart Transplant Wait List: VADS, Exceptions and Antibodies

Apr 5, 2017 4:30pm ‐ Apr 5, 2017 6:00pm

Identification: 010

(57) Trends in 1A Listing Exceptions in Heart Transplant (HT) Recipients Bridged by Left Ventricular Assist Device (LVAD) Type
Anthony Salimbangon, RN

(58) Left Ventricular Assist Device Is Protective Against Cardiac Transplant Delisting for Medical Unsuitability
Rebecca Cogswell, MD

(59) Age Dependent Risk of LVAD Used as a Bridge to Transplant and of Comorbidities on Post-Transplant Survival: An Analysis of ISHLT Registry
Marco Masetti, MD, PhD

(60) Impact of Sensitization and 4S Prioritization on Heart Transplantation Waiting Times in Canada
Natasha Aleksova, MD

(61) Revealing a New Mode of Sensitization Induced by Mechanical Circulatory Support Devices (MCS): Impact of Anti-AT1R Antibodies
Xiaohai Zhang, PhD

(62) Trends in 1A Listing Exceptions in Heart Transplant (HT) Recipients Bridged with Mechanical Circulatory Support (MCS)
Eugene DePasquale, MD


SESSION 11: Improving Prognosis in Chronic Lung Allograft Dysfunction

Apr 5, 2017 4:30pm ‐ Apr 5, 2017 6:00pm

Identification: 011

(63) Correlation Between Microbial Diversity, Lung Inflammation, and Chronic Lung Allograft Dysfunction
Liran Levy, MD

(64) Lung Bile Acid Correlation with Inflammation, Infection, CLAD and Survival
Musawir Ahmed, MD

(65) Matrix Metalloproteinase-7 May Be a Biomarker of Early Chronic Lung Rejection
Glen Westall, PhD, MD

(66) The Impact of De Novo Donor-Specific Antibodies on Bronchiolitis Obliterans Syndrome and Restrictive Allograft Syndrome
Ei Miyamoto, MD

(67) Role of Complement-Binding Anti-HLA Antibodies Detection as Early Predictor of Chronic Lung Dysfunction After Lung Transplantation
Olivier Brugière, MD, PhD

(68) Immunophenotyping Pre Total Lymphoid Irradiation for BOS After Lung Transplantation May Predict Response to Therapy
Bastian Schmack, MD


SESSION 12: Innovation in Pediatric MCS

Apr 5, 2017 4:30pm ‐ Apr 5, 2017 6:00pm

Identification: 012

(69) Reverse Remodeling After Placement of Pulsatile and Continuous Flow Left Ventricular Assist Device in Children with End-Stage Idiopathic Dilated Cardiomyopathy
Bibhuti Das, MD

(70) Are Implantable Cardioverter-Defibrillators Indicated in Pediatric Ventricular Assist Device Patients?
Anica Bulic, MD

(71) Post-Transplant Outcomes in Pediatric VAD Patients: A Pedimacs-PHTS Linkage Study
David Sutcliffe, MD

(72) In Vitro Examination of the VentriFlo™ True Pulse Pump for Failing Fontan Support
Phillip Trusty, BS

(73) Outcome of a Continous Flow Pump (Jarvik 2000) as Bridge to Transplantation or Destination Therapy in Pediatric Patients
Gianluigi Perri, MD, PhD

(74) Compassionate Deactivation of Ventricular Assist Devices in Children: A Survey of Pediatric VAD Clinicians’ Perspectives and Practices
Beth Kaufman, MD

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
completed on: 
rendered in: 
* - Indicates answer is required.